7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      [Brivaracetam for add-on treatment in focal epilepsy].

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Brivaracetam is the latest antiepileptic drug to be approved for adjunctive therapy in focal epilepsy and has a high affinity as a SV2A ligand. The aim of this review article is to summarize the data from the pivotal studies in which more than 2000 patients received brivaracetam. A significant median reduction in seizures from 30.5 % to 53.1 % for 50 mg/day, from 32.5 % to 37.2 % for 100 mg/day and 35.6 % for 200 mg/day could be demonstrated. Overall brivaracetam appears to be well-tolerated, with fatigue, dizziness and somnolence being the main adverse side effects. An immediate change from levetiracetam to brivaracetam at a conversion ratio of 10:1 to 15:1 seems feasible and could alleviate behavioral side effects related to treatment with levetiracetam. A swift permeability into brain tissue and a faster onset of action compared to levetiracetam suggest that brivaracetam could be useful in emergency situations.

          Related collections

          Author and article information

          Journal
          Nervenarzt
          Der Nervenarzt
          Springer Nature
          1433-0407
          0028-2804
          Oct 2016
          : 87
          : 10
          Affiliations
          [1 ] Epilepsiezentrum Frankfurt Rhein-Main, Klinik für Neurologie, J.W. Goethe-Universität, Frankfurt am Main, Deutschland. strzelczyk@med.uni-frankfurt.de.
          [2 ] Epilepsiezentrum Hessen, Klinik für Neurologie, Philipps-Universität, Marburg, Deutschland. strzelczyk@med.uni-frankfurt.de.
          [3 ] Epilepsiezentrum Frankfurt Rhein-Main, Klinik für Neurologie, J.W. Goethe-Universität, Frankfurt am Main, Deutschland.
          [4 ] Epilepsiezentrum Hessen, Klinik für Neurologie, Philipps-Universität, Marburg, Deutschland.
          Article
          10.1007/s00115-016-0163-4
          10.1007/s00115-016-0163-4
          27389600
          b8309270-0cd9-42bd-a75e-cfcc7c93554e
          History

          Emergency treatment,Antiepileptic drugs,Levetiracetam,Seizure,Adverse effects

          Comments

          Comment on this article